After announcing in September 2018 the successful activation of its subretinal photovoltaic implant in 5 French patients with dry AMD, Pixium Vision presented the results of its feasibility study at a conference in early March.

In September 2018, 5 patients with advanced atrophic dry AMD received the new generation PRIMA subretinal implant. Six months later, all had preserved their peripheral vision, and all are able to perceive light signals from central area.

Pixium Vision said today that its Prima miniature wireless photovoltaic sub-retinal implant has been activated in the first five patients. The patients all have severe vision loss from atrophic dry age-related macular degeneration.

Five people with severe vision loss will have an experimental chip implanted in their eyes to help them see. The 2 x 2 millimeter square implant is 30 microns thick, about a third of the thickness of a human hair. French regulators last week approved the trial of the bionic vision implant, which will be placed in people with an advanced type of retinal disease called dry age-related macular degeneration, or dry AMD.

After obtaining CE mark in July, Pixium Vision received NUB innovation reimbursement status 1 for IRIS^®II in Germany, and announced first implantation and activation of IRIS^®II in Spain in the ongoing multi-center clinical trial.

With the objective to raise awareness about blind people and their abilities, a guided adventure, with the aim to cross the Siberian Lake Baïkal in winter, will be followed by RFI and scientific researchers from February 24^th to March 2^nd, 2017.

Surgery revolution, nano-robotic growth, new bio-therapies, visual prosthesis... There have never been so many promises for improved treatments.